Niraparib in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and biallelic DNA-repair gene defects (DRD): Correlative measures of tumor response in phase II GALAHAD study.

Authors

• William Kelly

Publication/Presentation Date

2-2020

Volume

38

Issue

6

Published In/Presented At

DOI: 10.1200/JCO.2020.38.6_suppl.118

Disciplines

Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods

Department(s)

Administration and Leadership

Document Type

Article